Plasma Proteomics with the Evosep One
Availble on demand
Proteomics analysis of human blood offers an attractive and challenging pipeline for discovery of biomarkers. Over the last few years the need for, large cohort, plasma analysis using proteomic techniques has become more and more prevalent for both discovery and targeted workflows.
High throughput MS-based proteomics is being coupled with Machine learning, in order to identify significant biomarkers. Targeted workflows are then used to detect and quantify previously identified biomarkers.
Balancing depth, throughput and pragmatism in plasma proteomics
Talk by Roman Fischer, ASSOCIATE PROFESSOR AND HEAD OF DISCOVERY PROTEOMICS FACILITY at University of Oxford
Recent advances in robustness and throughput of LC-MS/MS platforms allow unprecedented coverage of clinical cohorts for biomarker discovery in acute disease and epidemiology. However, high analysis costs have to be met with pragmatism and what is archivable in a clinical environment, also with view on global emergencies such as the COVID pandemic.
High-throughput plasma proteomics enables robust biomarker discovery for liver disease
Talk by Lili Niu, Postdoc at University of Copenhagen, Novo Nordisk Foundation Center for Protein Research, Groups of Human Proteome Variation and Clinical Proteomics
Mass spectrometry (MS)-based clinical proteomics has a great potential to revolutionize disease detection. Previously we have identified novel proteins associated with liver disease using plasma proteomics leveraged by the BoxCar acquisition method. In this presentation, we show that BoxCar/DIA on an Evosep One coupled to quadrupole-Orbitrap mass spectrometers enables the robust identification of circulating biomarker panels for liver disease, surpassing existing clinical tests in terms of both diagnostic and prognostic power. The biomarker panels are further validated in an independent cohort. These results lay the foundation for developing a generic MS-based blood test for liver disease.